• Open Access

Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia

Authors

  • Misti Samaiya,

    1. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
    Search for more papers by this author
  • Sameer Bakhshi,

    1. Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
    Search for more papers by this author
  • Abhay A. Shukla,

    1. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
    Search for more papers by this author
  • Lalit Kumar,

    1. Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
    Search for more papers by this author
  • Shyam S. Chauhan

    Corresponding author
    1. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
      Prof. Shyam S. CHAUHAN, Ph.D., Room No. 3009, Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
      Tel.: (+91)11–26593272
      Fax: (+91)11–26588641
      E-mail: s_s_chauhan@hotmail.com
    Search for more papers by this author

Prof. Shyam S. CHAUHAN, Ph.D., Room No. 3009, Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
Tel.: (+91)11–26593272
Fax: (+91)11–26588641
E-mail: s_s_chauhan@hotmail.com

Abstract

The expression and significance of cathepsin L (CTSL) has been extensively studied in solid tumours. However no such information in chronic myeloid leukaemia (CML) was available. We investigated the activity and expression of this protease in peripheral blood mononuclear cells (PBMCs) of 47 adult CML patients. Thirty adults suffering from systemic diseases and 50 healthy volunteers served as controls. The mRNA levels of CTSL, its specific endogenous inhibitor cystatin C and transcriptional up-regulator vascular endothelial growth factor (VEGF) were quantitated by real-time qPCR. CTSL protease activity and its mRNA expression were significantly higher in CML chronic phase (CP) patients compared to CML accelerated phase/blast crisis (AP/BC) patients and controls (P≤ 0.001). VEGF whose expression was most pronounced in CP and declined (P≤ 0.001) in the advanced phases of the malignancy exhibited a strong positive correlation with CTSL expression (r= 0.97; P≤ 0.001). Cystatin C expression was significantly lower (P≤ 0.001) in CML and displayed inverse correlation with CTSL (r=−0.713; P≤ 0.001) activity. CTSL promoter was significantly hypomethylated in CML CP compared to CML AP/BC patients as well as controls. K562, a BC CML cell line displayed CTSL activity, expression and methylation status of CTSL promoter that was comparable to CML AP/BC patients. Treatment of these cells or PBMCs isolated from CML AP/BC patients with 5′-aza-cytidine resulted in a dramatic increase in CSTL activity and/or expression thereby demonstrating the role of promoter methylation in the stage specific expression of CTSL in CML. Differential expression of CTSL in CML at various stages of malignancy may prove useful in identification of the high-risk patients thereby facilitating better management of disease.

Ancillary